Blueprint Medicines Corp

-2.03 (-2.99%)
Products, Regulatory

Blueprint Medicines Announces Positive Top-Line Results From Pioneer Trial Of Ayvakit (Avapritinib) In Patients With Non-Advanced Systemic Mastocytosis Achieving Primary And All Key Secondary En

Published: 08/17/2022 11:23 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Announces Positive Top-line Results From Pioneer Trial of Ayvakit® (avapritinib) in Patients With Non-advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints.
Blueprint Medicines Corp - Ayvakit Showed a Superior Mean Change in Total Symptom Score (p=0.003), Compared to Placebo Plus Best Available Care.
Blueprint Medicines - Highly Significant Reductions Across All Objective Measures of Mast Cell Burden Reinforce Disease Modifying Activity of Ayvakit.
Blueprint Medicines Corp - Ayvakit Had a Favorable Safety Profile Compared to Control Arm, Supporting Potential for Long-term Treatment.
Blueprint Medicines Corp - Plan to Submit Supplemental New Drug Application to FDA in Q4 of 2022.